VRDN | tickerfilter.com

Fundamental analysis

24%

Profitability 25%

Dept financing 3%

Liquidity 75%

Performance 16%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.81%

1 Month

-9.33%

3 Months

-15.00%

6 Months

55.16%

1 Year

-11.87%

2 Year

-30.71%

Key data

Stock price

$19.46

P/E Ratio

-4.11

DAY RANGE

$18.88 - $19.84

EPS

-$4.18

52 WEEK RANGE

$11.99 - $27.20

52 WEEK CHANGE

-$8.95

MARKET CAP

937.904 M

YIELD

N/A

SHARES OUTSTANDING

63.890 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/11/2024

BETA

1.35

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,909,788

AVERAGE 30 VOLUME

$1,706,245

Company detail

CEO: Jonathan Violin
Region: US
Website: viridiantherapeutics.com
Employees: 50
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Viridian Therapeutics, Inc. develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED) The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

VRDN - Viridian Therapeutics, Inc.\DE